Selected patents issued March 12 by the U.S. Patent andTrademark Office

U.S. Class: 424-93Patent Number: 4,999,192Assignee: Mycogen Corp.Claims/description: 12 claims for the use of endotoxin-producing Bacillus thuringiensis to control coleoptera, such asbeetles and weevils.

U.S. Class: 424-94.63Patent Number: 4,999,194Assignee: Collaborative Research Inc.Claims/description: 7 claims for double-chain urokinaseplasminogen activators to treat thrombolytic diseases.

U.S. Class: 435-6Patent Number: 4,999,290Assignee: University of Texas SystemClaims/description: 27 claims for the use of antisenseoligonucleotides to detect genetic defects.

U.S. Class: 435-69.1Patent Number: 4,999,291Assignee: Amgen Inc.Claims/description: 5 claims for a DNA sequence encodinghuman pluripotent granulocyte colony-stimulating factor (G-CSF).

U.S. Class: 435-172.3Patent Number: 4,999,293Assignee: New England Biolabs Inc.Claims/description: 10 claims for a DNA sequence encoding theHhaI restriction endonuclease.

U.S. Class: 435-172.3Patent Number: 4,999,294Assignee: New England Biolabs Inc.Claims/description: 10 claims for a DNA sequence encoding theFokI restriction endonuclease.

U.S. Class: 435-235.1Patent Number: 4,999,296Assignee: NovaGene Inc. and Baylor College of MedicineClaims/description: 14 claims for a pseudorabies virus thatdoes not produce functional thymidine kinase.

U.S. Class: 514-2Patent Number: 4,999,339Assignee: Cetus Corp.Claims/description: 28 claims for combination therapy of IL-2and DTIC to treat melanoma.

U.S. Class: 530-350Patent Number: 4,999,421Assignee: Triton Biosciences Inc.Claims/description: 1 claim for a protein that is expressed bythe antisense strand of HTLV-1 virus.

U.S. Class: 530-351Patent Number: 4,999,422Assignee: Biogen N.V.Claims/description: 10 claims for a continuous method ofrefolding proteins to obtain the biologically activeconformation.

(c) 1997 American Health Consultants. All rights reserved.